Breaking Down SG&A Expenses: Genmab A/S vs Alkermes plc

A Tale of Two Biopharma Giants: Genmab A/S vs Alkermes plc

In the dynamic world of biopharmaceuticals, understanding the financial health of companies is crucial. Over the past decade, Genmab A/S and Alkermes plc have shown contrasting trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Genmab A/S has seen a staggering increase in SG&A expenses, growing by over 4,000%, reflecting its aggressive expansion and investment in innovation. In contrast, Alkermes plc's SG&A expenses have grown by approximately 245%, indicating a more steady and controlled growth strategy.

This divergence highlights the different strategic paths these companies have taken. While Genmab A/S focuses on rapid growth and market penetration, Alkermes plc appears to prioritize stability and sustainable development. Investors and industry analysts should consider these trends when evaluating the future potential and risk profiles of these biopharma leaders.